Curis, Inc. (CRIS)
Stock Price:
$1.44 USD
0.07 (5.11%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.42 -0.02 (-1.39%) Nov 27, 4:45 PM
Key Info
| Market Cap |
84.70M |
| Revenue (ttm) |
11.10M |
| Net Income (ttm) |
-31.00M |
| Shares Out |
58.82M |
| EPS (ttm) |
-0.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$1.44 |
| Previous Close |
$1.37 |
| Change ($) |
0.07 |
| Change (%) |
5.11% |
| Day's Open |
1.38 |
| Day's Range |
1.37 - 1.44 |
| Day's Volume |
592,013 |
| 52-Week Range |
0.62 - 3.59 |
More Stats
| Market Cap |
84.70M |
| Enterprise Value |
69.07M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.82M |
| Float |
n/a |
| EPS (basic) |
-0.82 |
| EPS (diluted) |
-0.77 |
| FCF / Share |
-0.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
430,882 |
| Short Ratio |
1.27 |
| Short % of Float |
n/a |
| Beta |
2.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.63 |
| PB Ratio |
n/a |
| Revenue |
11.10M |
| Operating Income |
-25.96M |
| Net Income |
-31.00M |
| Free Cash Flow |
-26.28M |
| Net Cash |
15.63M |
| Net Cash / Share |
0.27 |
| Gross Margin |
-115.35% |
| Operating Margin |
-233.89% |
| Profit Margin |
-279.30% |
| FCF Margin |
-236.80% |
| ROA |
-36.89% |
| ROE |
n/a |
| ROIC |
-489.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.75*
(229.86% upside)
Low
4.00
Current: $1.44
High
5.00
Target: 4.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 10.00 | 10.43 | 9.90 | 7.53 | 7.88 | 9.84 | 15.00 | 16.97 | 14.76 | 16.00 |
| Revenue Growth | -4.07% | 5.35% | 31.5% | -4.46% | -19.96% | -34.39% | -11.61% | 14.97% | -7.73% | - |
| Gross Profit | 9.50 | 9.87 | 9.40 | 7.13 | 7.47 | 9.50 | 14.80 | 16.80 | 14.76 | 16.00 |
| Operating Income | -24.36 | -29.33 | -49.76 | -58.04 | -56.48 | -15.86 | -9.42 | -18.62 | -7.20 | -5.64 |
| Net Income | -32.14 | -32.58 | -53.32 | -60.41 | -58.98 | -18.73 | -12.32 | -16.42 | -9.86 | -4.44 |
| Shares Outstanding | 33.18 | 33.12 | 29.83 | 26.56 | 24.67 | 17.19 | 16.47 | 15.81 | 15.27 | 14.99 |
| Earnings Per Share | -0.97 | -0.98 | -1.79 | -2.25 | -2.40 | -1.10 | -0.75 | -1.05 | -0.65 | -0.30 |
| Operating Cash Flow | -26.21 | -30.07 | -48.36 | -35.81 | -29.89 | -16.81 | -9.54 | -15.19 | -4.56 | -1.63 |
| Capital Expenditures | -0.04 | -0.09 | -0.19 | -0.33 | -0.02 | -0.09 | -0.15 | -0.10 | -0.18 | -0.18 |
| Free Cash Flow | -26.25 | -30.15 | -48.54 | -36.14 | -29.92 | -16.90 | -9.69 | -15.30 | -4.75 | -1.80 |
| Cash & Equivalents | 20.70 | 24.42 | 60.23 | 44.49 | 82.19 | 49.76 | 58.19 | 55.55 | 37.72 | 40.60 |
| Total Debt | 0.17 | 35.48 | 41.56 | 19.86 | 24.17 | 28.30 | 30.56 | 29.84 | - | - |
| Net Cash / Debt | 20.53 | -11.06 | 18.68 | 24.63 | 58.03 | 21.47 | 27.64 | 25.71 | 37.72 | 40.60 |
| Assets | 35.11 | 37.37 | 73.80 | 57.75 | 94.97 | 62.61 | 80.59 | 69.77 | 48.18 | 50.65 |
| Liabilities | 69.02 | 41.86 | 49.81 | 28.49 | 30.46 | 32.83 | 35.42 | 35.50 | 8.30 | 5.13 |
| Book Value | -33.91 | -4.50 | 23.99 | 29.27 | 64.51 | 29.78 | 45.17 | 34.27 | 39.88 | 45.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Curis, Inc. |
| Country |
United States |
| Employees |
28 |
| CEO |
James E. Dentzer |
Stock Information
| Ticker Symbol |
CRIS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRIS |
| IPO Date |
August 1, 2000 |
Description
Curis, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.